scholarly journals P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC

2017 ◽  
Vol 12 (1) ◽  
pp. S962
Author(s):  
Jose Carlos Ruffinelli ◽  
Arturo Navarro-Martin ◽  
Marta Doménech ◽  
Ramon Palmero ◽  
Susana Padrones ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Primary Tumor ◽  
Tumor Therapy

scholarly journals FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3952
Author(s):  
Andrea Gallamini ◽  
Michał Kurlapski ◽  
Jan Maciej Zaucha
Keyword(s):  
Treatment Outcome ◽  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Quantitative Methods ◽  
Present Review ◽  
Response To Treatment ◽  
Published Evidence ◽  
Pet Ct ◽  
Fdg Pet Ct

In the present review, the authors report the published evidence on the use of functional imaging with FDG-PET/CT in assessing the final response to treatment in Hodgkin lymphoma. Despite a very high overall Negative Predictive Value of post-chemotherapy PET on treatment outcome ranging from 94% to 86%, according to different treatment intensity, the Positive Predicting Value proved much lower (40–25%). In the present review the Authors discuss the role of PET to guide consolidation RT over a RM after different chemotherapy regimens, both in early and in advanced-stage disease. A particular emphasis is dedicated to the peculiar issue of the qualitative versus semi-quantitative methods for End-of Therapy PET scan interpretation. A short hint will be given on the role of FDG-PET to assess the treatment outcome after immune checkpoint inhibitors.

Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy

2021 ◽  
Author(s):  
Yin Qianmei ◽  
Su Zehong ◽  
Wang Guang ◽  
Li Hui ◽  
Gaojian Lian
Keyword(s):  
Tumor Immunity ◽  
Tumor Therapy ◽  
Treg Cells ◽  
Recent Advances

Altered Serotonergic Activity in Women with Dysphoric Premenstrual Syndromes

1993 ◽  
Vol 23 (1) ◽  
pp. 1-27 ◽  
Author(s):  
Uriel Halbreich ◽  
Henry Tworek
Keyword(s):  
Treatment Outcome ◽  
Menstrual Cycle ◽  
Luteal Phase ◽  
Symptomatic Treatment ◽  
Gonadal Hormones ◽  
Interactive System ◽  
Library Search ◽  
Serotonergic Activity ◽  
Late Luteal Phase

Objective: Dysphoric Premenstrual Syndromes (PMS) are quite prevalent and in some women they are severe enough to warrant treatment. Their pathophysiology is still unknown, despite increased interest and research. Here we review the possible role of serotonin in the multidimensional interactive pathophysiology of PMS. Method: Over 170 articles are reviewed. An extensive library search has been conducted and articles are included because of their relevance to: 1) the phenomenology of PMS; 2) the putative association of serotonergic (5-HT) activity with syndromes that occur premenstrually; 3) changes in 5-HT activity along the menstrual cycle, especially the late luteal phase; 4) influence of gonadal hormones on serotonergic functions; 5) endocrine strategies for assessment of 5-HT abnormalities; and 6) treatment studies of PMS with serotonergic agonists. Results and Conclusions: The data presented here suggest that post-synaptic serotonergic responsivity might be altered during the late-luteal-premenstrual phase of the menstrual cycle. Some serotonergic functions of women with PMS might be altered during the entire cycle and be associated with a vulnerability trait. It is hypothesized that gonadal hormones might cause changes in levels of activity of 5-HT systems as part of a multidimensional interactive system. Strategies to evaluate 5-HT activities in the context of the menstrual cycle are discussed—leading to the conclusion that the most promising approach is active stimulation with specific post-synaptic serotonin agonists. Treatment outcome studies of some imperfect compounds that are currently applied as a symptomatic treatment of PMS support the notion that 5-HT is involved in the pathophysiology of these syndromes.

Treatment of the Primary Tumor: Role of Organ-Preserving Surgery in Penile Cancer

2019 ◽  
pp. 817-831
Author(s):  
Arie Stewart Parnham ◽  
Gideon Adam Blecher ◽  
Suks Minhas
Keyword(s):  
Primary Tumor ◽  
Penile Cancer

scholarly journals Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53

2018 ◽  
Vol 19 (12) ◽  
pp. 3952 ◽  
Author(s):  
Maria Mrakovcic ◽  
Lauren Bohner ◽  
Marcel Hanisch ◽  
Leopold F. Fröhlich
Keyword(s):  
Cell Death ◽  
Tumor Cells ◽  
Histone Deacetylase ◽  
Stress Responses ◽  
Histone Deacetylase Inhibitors ◽  
Tumor Therapy ◽  
Regulatory System ◽  
Anticancer Activities ◽  
Mutational Status

Tumor development and progression is the consequence of genetic as well as epigenetic alterations of the cell. As part of the epigenetic regulatory system, histone acetyltransferases (HATs) and deacetylases (HDACs) drive the modification of histone as well as non-histone proteins. Derailed acetylation-mediated gene expression in cancer due to a delicate imbalance in HDAC expression can be reversed by histone deacetylase inhibitors (HDACi). Histone deacetylase inhibitors have far-reaching anticancer activities that include the induction of cell cycle arrest, the inhibition of angiogenesis, immunomodulatory responses, the inhibition of stress responses, increased generation of oxidative stress, activation of apoptosis, autophagy eliciting cell death, and even the regulation of non-coding RNA expression in malignant tumor cells. However, it remains an ongoing issue how tumor cells determine to respond to HDACi treatment by preferentially undergoing apoptosis or autophagy. In this review, we summarize HDACi-mediated mechanisms of action, particularly with respect to the induction of cell death. There is a keen interest in assessing suitable molecular factors allowing a prognosis of HDACi-mediated treatment. Addressing the results of our recent study, we highlight the role of p53 as a molecular switch driving HDACi-mediated cellular responses towards one of both types of cell death. These findings underline the importance to determine the mutational status of p53 for an effective outcome in HDACi-mediated tumor therapy.

scholarly journals Patient with Metastatic Process in the Skeleton of Unknown Etiology

2019 ◽  
pp. 135-142
Author(s):  
Majerníková M ◽  
Sedláček J ◽  
Monhart Z
Keyword(s):  
Multiple Myeloma ◽  
Primary Tumor ◽  
Case Reports ◽  
Unknown Etiology ◽  
Primary Process ◽  
Kidney Tumor ◽  
Complex Treatment ◽  
Benign Process ◽  
Metastatic Process

Bearing bone involvement is a possible sign of generalization variety of cancers. In many cases the process of bearing skeletal diagnosed at the time when the primary tumor is not obvious. The task of the physician is quickly to determine whether it is a benign process or not, and diagnosis of the primary process by which then determine the further progress of therapy. The search for causative bearing shell process, alternatively the primary tumor, is often common practice in the hands of internist. Departments of Clinical Oncology do not have to have sufficient capacity for complex treatment all of newly discovered deposits skeleton whose nature does not have to be always initially clear. Therefore, in the opinion of the authors in these cases, the role of internist as a significant diagnosis very important In our article, we introduce six case reports of patients who were bearing the ambiguous process of investigation of the skeleton in our department in 2014. In accordance with the literature data were represented kidney tumor, multiple myeloma, chondrosarcoma, and in one case the origo malignant process was not found.

scholarly journals Radiation therapy for oligometastatic cancer

2021 ◽  
Vol 10 (3) ◽  
pp. 5-14
Author(s):  
N.  V. Dengina ◽  
T. V. Mitin ◽  
I.  V. Tsimafeyeu ◽  
S.  V. Usychkin
Keyword(s):  
Radiation Therapy ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Malignant Tumors ◽  
Local Treatment ◽  
Supportive Therapy ◽  
Local Method ◽  
The Past ◽  
Oligometastatic Cancer

Current approaches to the treatment of patients with metastatic malignant tumors have changed significantly over the past decade. Instead of a purely palliative systemic or just supportive therapy, a large proportion of patients receive an aggressive local treatment directed not only to the primary tumor, but also to metastatic foci, and a number of studies demonstrate the advantage of such approach. This review provides information on the role of radiation therapy as a local method of treatment of cancer patients with oligometastases.

Sign in / Sign up

Export Citation Format

Share Document